Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule

Clinical Transplantation

Volumn 19, Issue 3, 2005, Pages 304-308

  Manito, Nicolás ^a   Kaplinsky, Edgardo J ^a   Roca, Josep ^a   Castells, Eduardo ^a   Saura, Emilio ^a   Gomez Hospital, Joan Antoni ^a   Esplugas, Enrique ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Heart transplantation; Immunosuppression; Mycophenolate mofetil; Renal insufficiency

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ATTENUATION; BACTERIAL INFECTION; BLOOD VESSEL GRAFT; CANCER; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT DYSFUNCTION; HEART TRANSPLANTATION; HERPES ZOSTER; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 19044362279     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00238.x     Document Type: Article

References (22)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
2. Kobashigawa J, Miller L, Renlund D et al. Randomised active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998: 66: 507
3. Sanchez V, Delgado JF, Blasco T et al. Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Transplant Proc 1999: 31: 2515
4. Dureau G, Obadia JF, Chuzel M, Boissonnat P. Introduction of mycophenolate mofetil and cyclosporine withdrawal in heart transplant patients with progressive deteriorating renal function. Transplant Proc 2000: 32: 461.
5. Tedoriya T, Keogh AM, Kusano K et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation potential role of mycophenolate mofetil. J Heart Lung Transplant 2002: 21: 976.
6. Ensley RD, Bristow MR, Olsen SL et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993: 56: 75.
7. Pisani BA, Mullen GM, Malinowska K et al. Plasma-pheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999: 18: 701.
8. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. J Heart Lung Transplant 2001: 20: 805.
9. Bertani T, Ferrazzi P, Schieppati A et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant recipients. Kidney int 1991: 40: 243.
10. Goldstein DJ, Zuech H, Sehgal W, Weinberg AL, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Transplantation 1997: 63: 664.
11. Muchmore JS, Cooper DK, Ye Y, Schlegel V, Pribil A, Zuhdi N. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant 1992: 11: 959.
12. Grewal HP, Thistlethwaite JR Jr, Loss GE et al. Corticosteroid cessation 1 week following renal transplantation using tacrólimus/mycophenolate mofetil based immunosuppression. Transplant Proc 1998: 30: 1378.
13. Budde K, Fritsche L, Geissler S et al. Steroid withdrawal in long-term cyclosporine A treated patients using mycophenolate mofetil: prospective randomized pilot study. Transplant Proc 2001: 33: 3250.
14. Renlund DG, Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996: 10 (1 Pt 2): 136.
15. Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997: 54: 285.
16. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000: 47: 215.
17. Kirklin JK, Bourge RC, Naftel DC et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994: 13: 444.
18. Kobashigawa JS, Renlund DG, Olsen SL et al. Initial results of RS-61443 for refractory cardiac rejection [Abstract 766-1]. J Am Coll Cardiol 1992: 19: 203A.
19. Hosenpud JD, Bennet LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalisation: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001: 72: 1662.
20. Meiser BM, Jagiello-Kraatz M, Pfeiffer M et al. The efficacy of mycophenolate mofetil treatment after heart transplantation is highly dependent on mycophenolate trough levels [Abstract 347]. Circulation 1997: 96: I-64.
21. Cantin B, Giannetti N, Parekh H et al. Mycophenolic acid concentrations in long term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 2002: 16: 196.
22. Schweizer RT, Meisterling LD. Tolerability of mycophenolate mofetil in organ transplant recipients. Transplant Proc 2001: 33: 2309.